| 1 | Nature Biotechnology | 66.4 | 99th | Q1 | SCIE | – | No |
| 2 | Molecular Cancer | 55 | 99th | Q1 | SCIE | – | Yes |
| 3 | Cell Stem Cell | 36.1 | 98th | Q1 | SCIE | – | No |
| 4 | Clinical and Translational Medicine | 33.8 | 98th | Q1 | SCIE | – | Yes |
| 5 | Medicinal Research Reviews | 29.1 | 97th | Q1 | SCIE | – | No |
| 6 | Pharmacological Reviews | 25.9 | 96th | Q1 | SCIE | – | No |
| 7 | Trends in Molecular Medicine | 24 | 96th | Q1 | SCIE | – | No |
| 8 | Experimental and Molecular Medicine | 22.6 | 95th | Q1 | SCIE | – | Yes |
| 9 | Molecular Aspects of Medicine | 21.6 | 95th | Q1 | SCIE | – | No |
| 10 | Journal of Nanobiotechnology | 20.2 | 94th | Q1 | SCIE | – | Yes |
| 11 | Biomarker Research | 18.5 | 94th | Q1 | SCIE | – | Yes |
| 12 | Genome Medicine | 18 | 93rd | Q1 | SCIE | – | Yes |
| 13 | Molecular Therapy | 17.9 | 93rd | Q1 | SCIE | – | No |
| 14 | Journal for ImmunoTherapy of Cancer | 16.6 | 92nd | Q1 | SCIE | – | Yes |
| 15 | Archives of Pharmacal Research | 13.6 | 91st | Q1 | SCIE | – | No |
| 16 | Cell Chemical Biology | 13.6 | 91st | Q1 | SCIE | – | No |
| 17 | Phytomedicine | 13.2 | 90th | Q1 | SCIE | – | No |
| 18 | EMBO Molecular Medicine | 13.1 | 90th | Q1 | SCIE | – | Yes |
| 19 | Pharmaceutical Biology | 12.4 | 89th | Q1 | SCIE | – | Yes |
| 20 | Cellular and Molecular Life Sciences | 12 | 89th | Q1 | SCIE | – | Yes |
| 21 | Stem Cell Research and Therapy | 11.9 | 88th | Q1 | SCIE | – | Yes |
| 22 | Molecular Biomedicine | 11.7 | 87th | Q1 | ESCI | – | Yes |
| 23 | Nucleic Acid Therapeutics | 11.4 | 87th | Q1 | SCIE | – | No |
| 24 | Acta Materia Medica | 11.4 | 86th | Q1 | – | – | Yes |
| 25 | Cancer Gene Therapy | 11.1 | 86th | Q1 | SCIE | – | No |
| 26 | Journal of Medicinal Chemistry | 11.1 | 85th | Q1 | SCIE | – | No |
| 27 | Molecular Therapy Nucleic Acids | 10.8 | 85th | Q1 | SCIE | – | Yes |
| 28 | BioFactors | 10.8 | 84th | Q1 | SCIE | – | No |
| 29 | Molecules | 10.3 | 84th | Q1 | SCIE | – | Yes |
| 30 | Nanomedicine: Nanotechnology, Biology, and Medicine | 10.3 | 83rd | Q1 | SCIE | – | No |
| 31 | Gene Therapy | 10.1 | 82nd | Q1 | SCIE | – | No |
| 32 | Probiotics and Antimicrobial Proteins | 10.1 | 82nd | Q1 | SCIE | – | No |
| 33 | Molecular Diagnosis and Therapy | 10 | 81st | Q1 | SCIE | – | No |
| 34 | Expert Reviews in Molecular Medicine | 9.9 | 81st | Q1 | SCIE | – | Yes |
| 35 | Expert Review of Vaccines | 9.9 | 80th | Q1 | SCIE | – | Yes |
| 36 | Molecular Medicine | 9.7 | 80th | Q1 | SCIE | – | Yes |
| 37 | Molecular Therapy Oncology | 9.6 | 79th | Q1 | SCIE | – | Yes |
| 38 | Molecular Oncology | 9.4 | 79th | Q1 | SCIE | – | Yes |
| 39 | Pharmaceuticals | 9 | 78th | Q1 | SCIE | – | Yes |
| 40 | Biotechnology and Applied Biochemistry | 8.9 | 77th | Q1 | SCIE | – | No |
| 41 | Mitochondrion | 8.9 | 77th | Q1 | SCIE | – | No |
| 42 | Pharmaceutical Research | 8.7 | 76th | Q1 | SCIE | – | No |
| 43 | Cellular Oncology | 8.6 | 76th | Q1 | SCIE | – | Yes |
| 44 | Expert Opinion on Therapeutic Targets | 8.6 | 75th | Q1 | SCIE | – | No |
| 45 | Journal of Molecular Medicine | 8.6 | 75th | Q1 | SCIE | – | No |
| 46 | EXCLI Journal | 8.6 | 74th | Q2 | SCIE | – | Yes |
| 47 | European Journal of Medicinal Chemistry Reports | 8.5 | 74th | Q2 | ESCI | – | Yes |
| 48 | Cancer Biology and Therapy | 8.4 | 73rd | Q2 | SCIE | – | Yes |
| 49 | Nature Mental Health | 8.1 | 72nd | Q2 | ESCI | – | No |
| 50 | Transplantation and Cellular Therapy | 8.1 | 72nd | Q2 | SCIE | – | No |
| 51 | Current Molecular Pharmacology | 7.8 | 71st | Q2 | SCIE | – | No |
| 52 | Molecular Therapy Methods and Clinical Development | 7.7 | 71st | Q2 | – | – | Yes |
| 53 | Molecular Pharmaceutics | 7.6 | 70th | Q2 | SCIE | – | No |
| 54 | Human Gene Therapy | 7.4 | 70th | Q2 | SCIE | – | No |
| 55 | Open Medicinal Chemistry Journal | 7.3 | 69th | Q2 | – | – | No |
| 56 | Molecular Medicine Reports | 7.3 | 68th | Q2 | SCIE | – | No |
| 57 | Virologica Sinica | 7.3 | 68th | Q2 | SCIE | – | No |
| 58 | Stem Cells | 7.3 | 67th | Q2 | SCIE | – | No |
| 59 | Biochimica et Biophysica Acta - Molecular Basis of Disease | 7.1 | 67th | Q2 | SCIE | – | No |
| 60 | Journal of Cellular and Molecular Medicine | 6.9 | 66th | Q2 | SCIE | – | Yes |
| 61 | ACS Chemical Biology | 6.9 | 65th | Q2 | SCIE | – | No |
| 62 | Frontiers in Genetics | 6.9 | 65th | Q2 | SCIE | – | Yes |
| 63 | Biointerface Research in Applied Chemistry | 6.8 | 65th | Q2 | – | – | No |
| 64 | Expert Review of Molecular Diagnostics | 6.8 | 64th | Q2 | SCIE | – | No |
| 65 | Molecular Informatics | 6.8 | 63rd | Q2 | SCIE | – | No |
| 66 | Journal of Trace Elements in Medicine and Biology | 6.7 | 63rd | Q2 | SCIE | – | No |
| 67 | Anti-Cancer Agents in Medicinal Chemistry | 6.7 | 62nd | Q2 | SCIE | – | No |
| 68 | Profiles of Drug Substances, Excipients and Related Methodology | 6.7 | 62nd | Q2 | – | – | No |
| 69 | Current Gene Therapy | 6.7 | 61st | Q2 | SCIE | – | No |
| 70 | Vascular Pharmacology | 6.5 | 61st | Q2 | SCIE | – | No |
| 71 | Current Medicinal Chemistry | 6.5 | 60th | Q2 | SCIE | – | No |
| 72 | Vaccine | 6.4 | 60th | Q2 | SCIE | – | No |
| 73 | Biomolecules and Therapeutics | 6.4 | 59th | Q2 | SCIE | – | No |
| 74 | Human Genomics | 6.4 | 58th | Q2 | SCIE | – | Yes |
| 75 | Journal of Natural Products | 6.3 | 58th | Q2 | SCIE | – | No |
| 76 | Journal of Molecular Diagnostics | 6.3 | 57th | Q2 | SCIE | – | No |
| 77 | Progress in Medicinal Chemistry | 6.3 | 57th | Q2 | – | – | No |
| 78 | Biomimetics | 6.2 | 56th | Q2 | SCIE | – | Yes |
| 79 | Human Genetics and Genomics Advances | 6.1 | 56th | Q2 | ESCI | – | Yes |
| 80 | Chemical Biology and Drug Design | 6.1 | 55th | Q2 | SCIE | – | No |
| 81 | Current Drug Targets | 6 | 55th | Q2 | SCIE | – | No |
| 82 | NeuroMolecular Medicine | 6 | 54th | Q2 | SCIE | – | No |
| 83 | Clinical Proteomics | 6 | 53rd | Q2 | SCIE | – | Yes |
| 84 | Bioinspiration and Biomimetics | 5.9 | 53rd | Q2 | SCIE | – | No |
| 85 | Analytical Cellular Pathology | 5.8 | 52nd | Q2 | SCIE | – | Yes |
| 86 | Nucleus (India) | 5.8 | 52nd | Q2 | ESCI | – | No |
| 87 | Biotechnology Journal | 5.7 | 51st | Q2 | SCIE | – | No |
| 88 | ChemMedChem | 5.7 | 51st | Q2 | SCIE | – | No |
| 89 | Pharmacogenomics Journal | 5.7 | 50th | Q2 | SCIE | – | No |
| 90 | RSC Medicinal Chemistry | 5.7 | 50th | Q2 | SCIE | – | No |
| 91 | Journal of Pharmacological Sciences | 5.7 | 49th | Q3 | SCIE | – | Yes |
| 92 | Bioorganic and Medicinal Chemistry | 5.6 | 48th | Q3 | SCIE | – | No |
| 93 | Function | 5.3 | 48th | Q3 | ESCI | – | Yes |
| 94 | Advances in Biological Regulation | 5.3 | 47th | Q3 | ESCI | – | No |
| 95 | Journal of Cardiovascular Translational Research | 5.3 | 47th | Q3 | SCIE | – | No |
| 96 | International Journal of Peptide Research and Therapeutics | 5.3 | 46th | Q3 | SCIE | – | No |
| 97 | Journal of Pharmacology and Experimental Therapeutics | 5.2 | 46th | Q3 | SCIE | – | No |
| 98 | Journal of Biochemical and Molecular Toxicology | 5.2 | 45th | Q3 | SCIE | – | No |
| 99 | Molecular Pharmacology | 5.2 | 44th | Q3 | SCIE | – | No |
| 100 | Phytochemical Analysis | 5.2 | 44th | Q3 | SCIE | – | No |
| 101 | Molecular Pain | 5.1 | 43rd | Q3 | SCIE | – | Yes |
| 102 | NMR in Biomedicine | 5.1 | 43rd | Q3 | SCIE | – | No |
| 103 | Journal of Experimental Pharmacology | 5.1 | 42nd | Q3 | – | – | Yes |
| 104 | Progress in Molecular Biology and Translational Science | 5 | 42nd | Q3 | – | – | No |
| 105 | Nuclear Medicine and Biology | 5 | 41st | Q3 | SCIE | – | No |
| 106 | Biomarker Insights | 4.9 | 41st | Q3 | ESCI | – | Yes |
| 107 | Current Molecular Medicine | 4.9 | 40th | Q3 | SCIE | – | No |
| 108 | Journal of Gene Medicine | 4.8 | 39th | Q3 | SCIE | – | No |
| 109 | Pharmacogenomics and Personalized Medicine | 4.8 | 39th | Q3 | SCIE | – | Yes |
| 110 | Cell Stress | 4.8 | 38th | Q3 | ESCI | – | Yes |
| 111 | Journal of Steroid Biochemistry and Molecular Biology | 4.8 | 38th | Q3 | SCIE | – | No |
| 112 | SLAS Discovery | 4.8 | 37th | Q3 | SCIE | – | Yes |
| 113 | Molecular Imaging | 4.7 | 37th | Q3 | SCIE | – | Yes |
| 114 | Planta Medica | 4.7 | 36th | Q3 | SCIE | – | No |
| 115 | ChemBioChem | 4.6 | 36th | Q3 | SCIE | – | No |
| 116 | Extremophiles | 4.5 | 35th | Q3 | SCIE | – | No |
| 117 | Bioorganic and Medicinal Chemistry Letters | 4.5 | 34th | Q3 | SCIE | – | No |
| 118 | Journal of Experimental Zoology Part B: Molecular and Developmental Evolution | 4.5 | 34th | Q3 | SCIE | – | No |
| 119 | Future Medicinal Chemistry | 4.4 | 33rd | Q3 | SCIE | – | No |
| 120 | SAR and QSAR in Environmental Research | 4.4 | 33rd | Q3 | SCIE | – | No |
| 121 | Journal of Medicinal and Chemical Sciences | 4.3 | 32nd | Q3 | – | – | No |
| 122 | Vaccine: X | 4.2 | 32nd | Q3 | ESCI | – | Yes |
| 123 | OMICS A Journal of Integrative Biology | 4.2 | 31st | Q3 | SCIE | – | No |
| 124 | Aspects of Molecular Medicine | 4 | 31st | Q3 | ESCI | – | Yes |
| 125 | Turkish Journal of Pharmaceutical Sciences | 4 | 30th | Q3 | ESCI | – | No |
| 126 | AIDS Research and Therapy | 3.8 | 29th | Q3 | SCIE | – | Yes |
| 127 | Assay and Drug Development Technologies | 3.8 | 29th | Q3 | SCIE | – | No |
| 128 | Journal of Peptide Science | 3.8 | 28th | Q3 | SCIE | – | No |
| 129 | Blood Cells, Molecules, and Diseases | 3.7 | 28th | Q3 | SCIE | – | No |
| 130 | Chemistry and Biodiversity | 3.7 | 27th | Q3 | SCIE | – | No |
| 131 | FASEB BioAdvances | 3.5 | 27th | Q3 | ESCI | – | Yes |
| 132 | Acta Naturae | 3.3 | 26th | Q3 | SCIE | – | No |
| 133 | Molecular Cytogenetics | 3.3 | 25th | Q3 | SCIE | – | Yes |
| 134 | Pharmacogenetics and Genomics | 3.2 | 25th | Q3 | SCIE | – | No |
| 135 | Advances in Biomarker Sciences and Technology | 3.1 | 24th | Q4 | – | – | Yes |
| 136 | GigaByte | 3.1 | 24th | Q4 | ESCI | – | Yes |
| 137 | Mitochondrial Communications | 3.1 | 23rd | Q4 | – | – | Yes |
| 138 | Pharmacogenomics | 3 | 23rd | Q4 | SCIE | – | No |
| 139 | Molecular and Cellular Oncology | 3 | 22nd | Q4 | ESCI | – | Yes |
| 140 | Viral Immunology | 3 | 22nd | Q4 | SCIE | – | No |
| 141 | Nanomedicine Research Journal | 3 | 21st | Q4 | – | – | Yes |
| 142 | Current Computer-Aided Drug Design | 2.9 | 20th | Q4 | SCIE | – | No |
| 143 | Infectious Disorders - Drug Targets | 2.9 | 20th | Q4 | – | – | No |
| 144 | Exploration of Medicine | 2.9 | 19th | Q4 | – | – | Yes |
| 145 | Journal of Asian Natural Products Research | 2.8 | 19th | Q4 | SCIE | – | No |
| 146 | Clinical and Translational Discovery | 2.8 | 18th | Q4 | ESCI | – | Yes |
| 147 | Current Pharmaceutical Analysis | 2.7 | 18th | Q4 | SCIE | – | No |
| 148 | Personalized Medicine | 2.7 | 17th | Q4 | SCIE | – | No |
| 149 | Central Nervous System Agents in Medicinal Chemistry | 2.6 | 17th | Q4 | – | – | No |
| 150 | Nucleosides, Nucleotides and Nucleic Acids | 2.3 | 16th | Q4 | SCIE | – | No |
| 151 | Expert Review of Precision Medicine and Drug Development | 2.3 | 15th | Q4 | ESCI | – | No |
| 152 | Future Cardiology | 2.2 | 15th | Q4 | ESCI | – | No |
| 153 | Discover Mental Health | 2.2 | 14th | Q4 | ESCI | – | Yes |
| 154 | EJNMMI Reports | 2.2 | 14th | Q4 | ESCI | – | Yes |
| 155 | Letters in Drug Design and Discovery | 2.2 | 13th | Q4 | SCIE | – | No |
| 156 | Eurobiotech Journal | 2 | 13th | Q4 | ESCI | – | Yes |
| 157 | International Journal of Molecular and Cellular Medicine | 1.9 | 12th | Q4 | ESCI | – | No |
| 158 | Tropical Journal of Natural Product Research | 1.9 | 12th | Q4 | – | – | No |
| 159 | Cardiovascular and Hematological Disorders - Drug Targets | 1.8 | 11th | Q4 | – | – | No |
| 160 | Current Enzyme Inhibition | 1.5 | 10th | Q4 | – | – | No |
| 161 | Topics in Medicinal Chemistry | 1.4 | 10th | Q4 | – | – | No |
| 162 | Current Cancer Therapy Reviews | 1.3 | 9th | Q4 | ESCI | – | No |
| 163 | Turkish Computational and Theoretical Chemistry | 1.3 | 9th | Q4 | – | – | No |
| 164 | OBM Genetics | 1.2 | 8th | Q4 | – | – | No |
| 165 | Pteridines | 1.2 | 8th | Q4 | – | – | Yes |
| 166 | Yaoxue Xuebao | 1.1 | 7th | Q4 | – | – | No |
| 167 | Stem Cell Biology and Regenerative Medicine | 1.1 | 6th | Q4 | – | – | No |
| 168 | Proceedings of the Shevchenko Scientific Society. Medical Sciences | 1 | 6th | Q4 | – | – | Yes |
| 169 | Methods in Pharmacology and Toxicology | 0.9 | 5th | Q4 | – | – | No |
| 170 | Clinical and Experimental Morphology | 0.7 | 5th | Q4 | – | – | No |
| 171 | Advances in Biochemistry in Health and Disease | 0.7 | 4th | Q4 | – | – | No |
| 172 | Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | 0.6 | 4th | Q4 | ESCI | – | No |
| 173 | Current Pharmacogenomics and Personalized Medicine | 0.5 | 3rd | Q4 | – | – | No |
| 174 | Cellular Therapy and Transplantation | 0.4 | 2nd | Q4 | – | – | No |
| 175 | VacciMonitor | 0.4 | 1st | Q4 | – | – | Yes |
| 176 | Progress in Drug Research | 0.2 | 1st | Q4 | – | – | No |
| 177 | Chinese Journal of Cancer Biotherapy | 0.2 | 0th | Q4 | – | – | No |
| 178 | European Pharmaceutical Review | 0.2 | 0th | Q4 | – | – | No |